Clinical trials: Glucose Variability
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
This is a randomized, double-blind, active control, parallel group, exploratory phase 4 study to compare the effect of teneligliptin versus sitagliptin on glucose variability when added on to metformin in patients with…
- Trial name
- NCT02512523
- Testing
- Teneligliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Handok Inc.
Type 2 Diabetes Mellitus
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once…
- Trial name
- TRACK (NCT02771093)
- Testing
- Trelagliptin, Alogliptin
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
The purpose of this study is to measure how much of the study drug or insulin glargine gets into the blood stream and how long it takes the body to get rid of it. The effect of exercise will also be evaluated.
- Trial name
- NCT01784211
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (insulin detemir) under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00659295)
- Testing
- insulin detemir
- Where
- 13 sites in Belgium, Czechia and 11 more
- Volunteers
- 51,170 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02318693
- Testing
- Sitagliptin, Glibenclamide
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Aneurysmal Subarachnoid Hemorrhage
Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy
The purpose of this study is to determine the efficacy and safety of a diabetes-specific tube feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically ill patients receiving insulin treatment for…
- Trial name
- NCT02503527
- Testing
- Diben 1.5 kcal HP, Fresubin HP Energy Fibre (1.5 kcal)
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Fresenius Kabi
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes
The purpose of this study is to compare the kinetics and biodynamics of inhaled Technosphere Insulin with those of subcutaneous (SC) regular human insulin.
- Trial name
- NCT00511719
- Testing
- Technosphere Insulin, Actrapid
- Volunteers
- 13 people
- Sponsor
- Mannkind Corporation
Insulin Resistance
Impact of Starch Digestibility on Glycemic Variability and Control, Cardiometabolic and Inflammatory Profiles, Microbiota and Intestinal Health in Subjects With Insulin Resistance
To study the potential impact of a diet rich in both Slowly Digestible Starch (SDS) and Resistant Starch (RS), we propose a 2-month nutritional intervention study in which we will study the evolution of carbohydrate variability…
- Trial name
- GLYMICARE (NCT07408479)
- Testing
- Balanced diet high in Slowly Digestible Starch and Resistant Starch, Balanced diet low in Slowly Digestible Starch and Resistant Starch
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Healthy
Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring
This is a two-cohort, crossover pilot study to determine interstitial glucose levels coincident with the consumption of a novel carbohydrate blocking supplement.
- Trial name
- NCT05832463
- Testing
- Carbohydrate blocking supplement (CBS)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- dōTERRA International
Diabetes
Distinguishing Participant Groups Using Autonomic Dysfunction
A study population with impaired fasting glucose levels, impaired glucose tolerance levels and diabetes (with or without complications) along with healthy patients will be chosen as participants.
- Trial name
- NCT05199350
- Testing
- Device Name: ANSiscope
- Where
- India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- DyAnsys, Inc.
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes…
- Trial name
- NCT03202563
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg, Diet/exercise questionnaire
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- LG Chem
Type 1 Diabetes Mellitus
PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)
Primary Objective: To characterize the within-subject variability in systemic exposure pharmacokinetic (PK) to insulin of a replicate single dose of Afrezza inhaled Technosphere Insulin (TI) in T1DM patients in a euglycemic clamp…
- Trial name
- NCT02485327
- Testing
- Technosphere Insulin SAR439065 Afrezza®
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus (T2DM)
Glycemic Variability of Combination Therapies in T2DM
Glycemic Variability of Combination Therapies in T2DM
- Trial name
- NCT07442006
- Testing
- Empagliflozin/Metformin, Anagliptin, Metformin
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- JW Pharmaceutical
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01545791)
- Testing
- insulin detemir
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 1,037 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).
- Trial name
- NCT00272077
- Testing
- Insuline glargine
- Sponsor
- Sanofi